CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a
humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult
subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in
combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with
pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.